[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100247241":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":22,"centralContacts":28,"locations":22,"responsibleParty":34,"collaborators":22,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":22,"eligibilityCriteria":42,"healthyVolunteers":38,"sex":43,"minAge":44,"maxAge":45,"enrollmentInfo":46,"targetDuration":22,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":56,"overallStatus":58,"whyStopped":22,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":22},{"fullName":5,"class":6},"The First People's Hospital of Changzhou","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"Temozolomide","Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg\u002Fm2\u002Fday for 5 consecutive days, repeated every 28 days",[12],"Drug: Temozolomide",{"label":14,"type":6,"description":15,"interventionNames":16},"Temozolomide+CIK","Autologous cytokine-induced killer cells were transfer via venous one week after Temozolomide treat",[17],"Biological: CIK",[19,23],{"type":20,"name":9,"description":10,"armGroupLabels":21,"otherNames":22},"DRUG",[9],null,{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":22},"BIOLOGICAL","CIK","The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat",[14],[29],{"name":30,"role":31,"phone":32,"phoneExt":22,"email":33},"Jingting Jiang, M.D","CONTACT","8651968870978","wcpjjt@163.com",{"type":35,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100247241","phase-4-effect-of-cytokine-induced-killer-cells-for-advanced-malignant-gliomas-100247241",false,"NCT02496988","Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas","A Study of CIK in Combination With Temozolomide With and Without Radiation in Adults With Advanced Malignant Gliomas","Inclusion Criteria:\n\n* Subjects with documented histologically confirmed primary grade 4 advanced malignant glioma.\n* No more than 3 prior relapses or prior systemic treatments.\n* Recurrent disease documented by MRI after prior therapy.\n* Must have at least one site of bidimensionally measurable disease:\n\narchived tissue from the initial diagnosis of advanced malignant glioma or upon transformation to advanced malignant glioma are available for central review within approximately 4 weeks after enrollment.\n\n* Completed at least one full cycle of temozolomide of 200 mg\u002Fm2\u002Fday administered on Days 1-5 of a 28-day cycle, without unacceptable toxicity or progression.\n* Karnofsky performance status of 60 or more. Adequate organ and bone marrow function as defined by hematological and serum chemistry limits.\n* At least 18 years old.\n* Both men and women must practice adequate contraception.\n* Informed consent.\n\nExclusion Criteria:\n\n* Progressed while on temozolomide.\n* Evidence of acute intracranial or intratumoral hemorrhage \\> Grade 1.\n* Not recovered from the toxic effects of prior therapy.\n* Pregnant or breast feeding.\n* History of diabetes mellitus.\n* Uncontrolled intercurrent illness.\n* Congestive heart failure, unstable angina, or a myocardial infarction within 3 months of entering the study.\n* HIV positive.\n* Diagnosis of another malignancy may exclude subject from study.","ALL","18 Years","80 Years",{"count":47,"type":48},120,"ESTIMATED","INTERVENTIONAL",[51],"PHASE4","The purpose of this study is to determine whether combining of Temozolomide and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with Advanced Malignant Gliomas. The effectiveness and safety of CIK cells for the treatment of Malignant Glioma is also evaluated.",[54,55],"Cytokine-Induced Killer Cells","Advanced Milignant Gliomas",[54,57,9],"Milignant Gliomas","NOT_YET_RECRUITING","2015-07-13",{"date":61,"type":48},"2015-07-14",{"date":63,"type":22},"2015-07",{"date":65,"type":48},"2030-07",{"name":5,"class":6}]